Literature DB >> 7993796

The progression of HCV-associated liver disease in a cohort of haemophilic patients.

P Telfer1, C Sabin, H Devereux, F Scott, G Dusheiko, C Lee.   

Abstract

We have studied morbidity and mortality related to hepatitis C virus infection in haemophilic patients treated at our centre. 11/255 HCV seropositive patients have developed hepatic decompensation. 20 years after first exposure to lyophilized clotting factor concentrate the risk of hepatic decompensation is estimated to be 10.8% (95% CI 3.8-17.8%). There is a significantly increased risk associated with HIV infection, and also with increased age. For HIV seropositive patients the rates of decline in CD4 lymphocyte count and the development of p24 antigenaemia are significant risk factors for hepatic decompensation. Cirrhosis was seen in 9/19 HIV seropositive patients at post mortem. There was an association of cirrhosis with increased age but not with CD4 count, p24 antigenaemia, or AIDS. In conclusion, HCV infection is associated with serious liver disease in haemophilic patients, but so far this has been restricted to a minority of those at risk. HIV co-infection accelerates progression to hepatic decompensation, and we speculate that this is probably due to enhanced HCV replication in the presence of immune deficiency.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7993796     DOI: 10.1111/j.1365-2141.1994.tb08312.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  38 in total

Review 1.  Reciprocal interaction of human immunodeficiency virus and hepatitis C virus infections.

Authors:  K E Nelson; D L Thomas
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

2.  Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs.

Authors:  M G Ghany; C Leissinger; R Lagier; R Sanchez-Pescador; A S Lok
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

Review 3.  Analytical and biological variables influencing quantitative hepatitis C virus (HCV) measurement in HIV-HCV coinfection.

Authors:  C L Cooper; Curtis L Cooper; Paul MacPherson; William Cameron
Journal:  Can J Gastroenterol       Date:  2006-01       Impact factor: 3.522

4.  Distribution and effects of polymorphic RANTES gene alleles in HIV/HCV coinfection -- a prospective cross-sectional study.

Authors:  Golo Ahlenstiel; Agathe Iwan; Jacob Nattermann; Karin Bueren; Jurgen K Rockstroh; Hans H Brackmann; Bernd Kupfer; Olfert Landt; Amnon Peled; Tilman Sauerbruch; Ulrich Spengler; Rainer P Woitas
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

Review 5.  Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.

Authors:  Asmaa-Ibrahim Gomaa; Shahid-A Khan; Mireille-B Toledano; Imam Waked; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

6.  Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection.

Authors:  Vincent Lo Re; Kevin Haynes; Kimberly A Forde; A Russell Localio; Rita Schinnar; James D Lewis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-09       Impact factor: 2.890

7.  Hepatitis C and HIV-1 coinfection.

Authors:  A H Mohsen; P Easterbrook; C B Taylor; S Norris
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 8.  Hepatitis C virus infection in children coinfected with HIV: epidemiology and management.

Authors:  Massimo Resti; Chiara Azzari; Flavia Bortolotti
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

9.  Characteristics of hepatitis C virus infection in HIV-infected people.

Authors:  C L Cooper; A D Badley; J B Angel
Journal:  Can J Infect Dis       Date:  2001-05

10.  The management of chronic viral hepatitis: A Canadian consensus conference 2004.

Authors:  Morris Sherman; Vincent Bain; Jean-Pierre Villeneuve; Robert P Myers; Curtis Cooper; Steven Martin; Catherine Lowe
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-11       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.